ANIPMEDIUM SIGNALFINANCIAL10-K

ANIP shows strong balance sheet expansion with cash nearly doubling and equity growing by one-third, though operating expenses increased meaningfully across SG&A and R&D.

The substantial cash increase to $285.6M alongside growing stockholders' equity suggests either successful fundraising activities or strong operational cash generation, providing enhanced financial flexibility. However, the 27% increase in SG&A expenses indicates rising operational costs that warrant monitoring for efficiency trends.

Comparing 2026-02-27 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

ANIP's financial position strengthened considerably with cash nearly doubling to $285.6M and stockholders' equity growing 34% to $540.7M, while current assets expanded 43% alongside a proportional increase in current liabilities. Operating expenses grew across the board with SG&A up 27% and R&D increasing 16%, though interest expense declined substantially. The overall picture suggests meaningful business expansion or recent capital-raising activities, with the company maintaining strong liquidity despite higher operational spending.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+97.1%
$144.9M→$285.6M

Cash position surged 97.1% — strong cash generation or capital raise providing significant financial cushion.

Interest Expense
P&L
-64.8%
$1.3M→$467K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Current Liabilities
Balance Sheet
+43.6%
$193.7M→$278.1M

Current liabilities surged 43.6% — significant near-term obligations; verify ability to meet short-term debt.

Current Assets
Balance Sheet
+42.7%
$527.7M→$753.1M

Current assets grew 42.7% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+33.9%
$403.7M→$540.7M

Equity base grew 33.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Dividends Paid
Cash Flow
-28.8%
$1.6M→$1.2M

Dividend reduced 28.8% — monitor management commentary on capital allocation priorities.

SG&A Expense
P&L
+27.3%
$249.6M→$317.7M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Accounts Receivable
Balance Sheet
+26.8%
$221.7M→$281.1M

Receivables grew 26.8% — monitor days sales outstanding for collection efficiency.

Net Interest Income
P&L
-22%
$16.0M→$12.5M

Net interest income declined 22% — margin compression from rate changes or funding cost increases.

R&D Expense
P&L
+15.9%
$44.6M→$51.7M

R&D investment increased 15.9% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-02-28
ADDED
A s of February 20, 2026, 22,414,104 shares of common stock and 10,864 shares of Class C special stock of the registrant were outstanding.
All statements other than statements of historical fact contained in this Annual Report on Form 10-K are forward-looking statements.
In some cases, you can identify forward-looking statements by terms such as anticipates, may, will, should, could, expects, estimates, plans, potential, future, believes, intends, continue, other words of similar meaning, derivations of such words, and the use of future dates.
Forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors, some of which cannot be predicted or quantified , that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.
Factors that might cause such a difference include, but are not limited to, those discussed under Part I, Item 1A, Risk Factors and elsewhere in this Annual Report on Form 10-K, as well as in our other periodic reports filed with the United States ( U.S.
+7 more — sign up free →
REMOVED
As of February 21, 2025, 21,762,646 shares of common stock and 10,864 shares of Class C Special stock of the registrant were outstanding.
Form 10-K Summary 160 Signatures 161 Ta b l e of Contents In this annual report, references to ANI Pharmaceuticals, ANI, the Company, we, us, and our refer, unless the context requires otherwise, to ANI Pharmaceuticals, Inc., a Delaware corporation, and its consolidated subsidiaries.
Such statements include, but are not limited to, statements about future operations, strategies and growth potential, the revenue potential (licensing, royalty and sales) of products we sell, development timelines, expected timeframe for submission of new drug applications, abbreviated new drug applications, or supplemental new drug applications to the U.S.
Food and Drug Administration (the FDA ), pipeline or potential markets for our products, selling and marketing strategies a nd associated costs to support the sales of Purified Cortrophin Gel (Repository Corticotropin Injection USP) ( Cortrophin Gel ), the closing of the acquisition of Alimera Sciences, Inc.
( Alimera ), impact of accounting principle s, litigation expenses, liquidity and capital resources, the impact of global pandemics on our business, and other statements that are not historical in nature, particularly those that utilize terminology such as anticipates, will, expects, plans, potential, future, believes, intends, continue, other words of similar meaning, derivations of such words, and the use of future dates.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →